Literature DB >> 15771232

Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes.

Thomayant Prueksaritanont1, Karen M Richards, Yue Qiu, Kristine Strong-Basalyga, Alisha Miller, Chunze Li, Roy Eisenhandler, Edward J Carlini.   

Abstract

PURPOSE: The induction potential of different fibric acid derivatives on human drug metabolizing enzymes was evaluated to help assess the role of enzyme induction on pharmacokinetic drug interactions.
METHODS: Effects of gemfibrozil, fenofibric acid, and clofibric acid on expression levels of cytochromes P450 (CYPs) 3A4 and 2C8 and UDP-glucuronyltransferase (UGT) 1A1 were evaluated in primary human hepatocyte cultures. The potential for these fibrates to activate human pregnane X receptor (PXR) also was studied in a cell-based PXR reporter gene assay.
RESULTS: All three fibrates caused increases in mRNA levels of CYP3A4 (2- to 5-fold), CYP2C8 (2- to 6-fold), and UGT1A1 (2- to 3-fold). On average, the effects on CYP3A4 were less than (< or =30% of rifampin), while those on CYP2C8 and UGT1A1 were comparable to or slightly higher than (up to 200% of rifampin) the corresponding effects observed with rifampin (10 microM). Consistent with the mRNA results, all fibrates caused moderate (approximately 2- to 3-fold) increases in CYP3A4 activity (measured by testosterone 6beta hydroxylase), as compared to about a 10-fold increase by rifampin. Significant increases (3- to 6-fold) in amodiaquine N-deethylase (a functional probe for CYP2C8 activity) also were observed with clofibric acid, fenofibric acid, and rifampin, in agreement with the mRNA finding. However, in contrast to the mRNA induction, marked decreases (>60%) in CYP2C8 activity were obtained with gemfibrozil treatment. Consistent with this finding, co-incubation of amodiaquine with gemfibrozil, but not with fenofibric acid, clofibric acid, or rifampin, in human liver microsomes or hepatocytes resulted in significantly decreased amodiaquine N-deethylase activity (IC50 = 80 microM for gemfibrozil, >500 microM for fenofibric or clofibric acid, and >50 microM for rifampin). Similar to rifampin, all three fibrates caused a modest change in the glucuronidation of chrysin, a nonspecific substrate of UGTs. No significant activation on human pregnane X receptor (PXR) was observed with the three fibrates in a PXR reporter gene assay.
CONCLUSIONS: In human hepatocytes, both fenofibric acid and clofibric acid are inducers of CYP3A4 and CYP2C8. Gemfibrozil is also an inducer of CYP3A4, but acts as both an inducer and an inhibitor of CYP2C8. In this system, all fibrates are weak inducers of UGT1A1. The enzyme inducing effects of fibrates appear to be mediated via a mechanism(s) other than PXR activation. These results suggest that fibrates may have potential to cause various pharmacokinetic drug interactions via their differential effects on enzyme induction and/or inhibition.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15771232     DOI: 10.1007/s11095-004-9011-5

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  38 in total

1.  Learning from the cerivastatin experience.

Authors:  J A Farmer
Journal:  Lancet       Date:  2001-10-27       Impact factor: 79.321

2.  Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate.

Authors:  Xue-Qing Li; Anders Björkman; Tommy B Andersson; Marianne Ridderström; Collen M Masimirembwa
Journal:  J Pharmacol Exp Ther       Date:  2002-02       Impact factor: 4.030

3.  Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in the human hepatoma cell line hep G2.

Authors:  T Walle; Y Otake; A Galijatovic; J K Ritter; U K Walle
Journal:  Drug Metab Dispos       Date:  2000-09       Impact factor: 3.922

Review 4.  Clinical pharmacokinetics of fibric acid derivatives (fibrates).

Authors:  D B Miller; J D Spence
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

5.  Mechanistic studies on metabolic interactions between gemfibrozil and statins.

Authors:  Thomayant Prueksaritanont; Jamie J Zhao; Bennett Ma; Brad A Roadcap; Cuyue Tang; Yue Qiu; Lida Liu; Jiunn H Lin; Paul G Pearson; Thomas A Baillie
Journal:  J Pharmacol Exp Ther       Date:  2002-06       Impact factor: 4.030

6.  Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.

Authors:  Jasminder Sahi; Christopher B Black; Geraldine A Hamilton; Xianxian Zheng; Summer Jolley; Kelly A Rose; Darryl Gilbert; Edward L LeCluyse; Michael W Sinz
Journal:  Drug Metab Dispos       Date:  2003-04       Impact factor: 3.922

7.  Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans.

Authors:  Arthur J Bergman; Gail Murphy; Joanne Burke; Jamie J Zhao; Robert Valesky; Lida Liu; Kenneth C Lasseter; Weili He; Thomayant Prueksaritanont; Yue Qiu; Alan Hartford; Jose M Vega; John F Paolini
Journal:  J Clin Pharmacol       Date:  2004-09       Impact factor: 3.126

8.  Activators of the rat pregnane X receptor differentially modulate hepatic and intestinal gene expression.

Authors:  Dylan P Hartley; Xudong Dai; Yudong D He; Edward J Carlini; Bonnie Wang; Su-Er W Huskey; Roger G Ulrich; Thomas H Rushmore; Raymond Evers; David C Evans
Journal:  Mol Pharmacol       Date:  2004-05       Impact factor: 4.436

9.  Gemfibrozil greatly increases plasma concentrations of cerivastatin.

Authors:  Janne T Backman; Carl Kyrklund; Mikko Neuvonen; Pertti J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  2002-12       Impact factor: 6.875

10.  Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance.

Authors:  Carl Kyrklund; Janne T Backman; Mikko Neuvonen; Pertti J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  2003-06       Impact factor: 6.875

View more
  25 in total

1.  Validation of an LC/MS method for the determination of gemfibrozil in human plasma and its application to a pharmacokinetic study.

Authors:  Joseph E Rower; Lane R Bushman; Kyle P Hammond; Rajendra S Kadam; Christina L Aquilante
Journal:  Biomed Chromatogr       Date:  2010-12       Impact factor: 1.902

2.  Comparative risk of severe hypoglycemia among concomitant users of thiazolidinedione antidiabetic agents and antihyperlipidemics.

Authors:  Charles E Leonard; Xu Han; Warren B Bilker; James H Flory; Colleen M Brensinger; David A Flockhart; Joshua J Gagne; Serena Cardillo; Sean Hennessy
Journal:  Diabetes Res Clin Pract       Date:  2016-03-14       Impact factor: 5.602

3.  Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.

Authors:  Christina L Aquilante; Lisa A Kosmiski; David W A Bourne; Lane R Bushman; Elizabeth B Daily; Kyle P Hammond; Charles W Hopley; Rajendra S Kadam; Alexander T Kanack; Uday B Kompella; Merry Le; Julie A Predhomme; Joseph E Rower; Maha S Sidhom
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

4.  Single and chronic administration of ciprofibrate or of ciprofibrate-glycinate in male Fischer 344 rats: comparison of the effects on morphological and biochemical parameters in liver and blood.

Authors:  Amelie Lupp; Elke Karge; Manfred Danz; Thomas Deufel; Herbert Oelschläger; Wolfgang Klinger
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jul-Sep       Impact factor: 2.441

5.  CYP2C8 Is a Novel Target of Peroxisome Proliferator-Activated Receptor α in Human Liver.

Authors:  Ngome L Makia; Joyce A Goldstein
Journal:  Mol Pharmacol       Date:  2015-10-14       Impact factor: 4.436

6.  Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.

Authors:  Thomayant Prueksaritanont; Xiaoyan Chu; Raymond Evers; Stephanie O Klopfer; Luzelena Caro; Prajakti A Kothare; Cynthia Dempsey; Scott Rasmussen; Robert Houle; Grace Chan; Xiaoxin Cai; Robert Valesky; Iain P Fraser; S Aubrey Stoch
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

7.  Effect of gemfibrozil on the pharmacokinetics of pioglitazone.

Authors:  Li-Jing Deng; Feng Wang; Huan-De Li
Journal:  Eur J Clin Pharmacol       Date:  2005-11-08       Impact factor: 2.953

8.  In vitro glucuronidation of fenofibric acid by human UDP-glucuronosyltransferases and liver microsomes.

Authors:  Jelena Tojcic; Marie-Odile Benoit-Biancamano; Michael H Court; Robert J Straka; Patrick Caron; Chantal Guillemette
Journal:  Drug Metab Dispos       Date:  2009-08-06       Impact factor: 3.922

Review 9.  The transcriptional regulation of the human CYP2C genes.

Authors:  Yuping Chen; Joyce A Goldstein
Journal:  Curr Drug Metab       Date:  2009-07-15       Impact factor: 3.731

Review 10.  Myopathy with statin-fibrate combination therapy: clinical considerations.

Authors:  Terry A Jacobson
Journal:  Nat Rev Endocrinol       Date:  2009-07-28       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.